Docetaxel

Generic Name
Docetaxel
Brand Names
Taxotere, Docetaxel Accord, Docetaxel Kabi
Drug Type
Small Molecule
Chemical Formula
C43H53NO14
CAS Number
114977-28-5
Unique Ingredient Identifier
699121PHCA
Background

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication

Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
Associated Therapies
-
Clinical Trials
Related News

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

First Posted Date
2024-04-17
Last Posted Date
2024-07-17
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT06370871

Efficacy and Toxicity of Docetaxel as a Radiosenstizer in Head and Neck Cancer

Phase 2
Not yet recruiting
Conditions
Head and Neck Cancer
First Posted Date
2024-04-11
Last Posted Date
2024-04-11
Lead Sponsor
Assiut University
Target Recruit Count
30
Registration Number
NCT06360978

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

First Posted Date
2024-04-10
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
450
Registration Number
NCT06356311
Locations
🇨🇳

Hunan Cancer Hospital ( Site 3014), Changsha, Hunan, China

🇨🇳

Xinjiang Medical University Cancer Hospital - Urumchi-The No.11 of Surgery building ( Site 3010), Urumchi, Xinjiang, China

🇩🇪

Städtisches Krankenhaus Kiel-2. Medizinische Klinik ( Site 1306), Kiel, Schleswig-Holstein, Germany

and more 111 locations

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

First Posted Date
2024-04-09
Last Posted Date
2024-12-09
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
220
Registration Number
NCT06353386
Locations
🇨🇦

Centre Hospitalier de l'Université de Montréal ( Site 0200), Montréal, Quebec, Canada

🇵🇱

Uniwersyteckie Centrum Kliniczne ( Site 1405), Gdansk, Pomorskie, Poland

🇬🇧

Addenbrooke's Hospital ( Site 1902), Cambridge, Cambridgeshire, United Kingdom

and more 50 locations

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

First Posted Date
2024-04-04
Last Posted Date
2024-11-28
Lead Sponsor
University of Chicago
Target Recruit Count
74
Registration Number
NCT06348134
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

First Posted Date
2024-04-04
Last Posted Date
2024-12-03
Lead Sponsor
AstraZeneca
Target Recruit Count
589
Registration Number
NCT06346392
Locations
🇻🇳

Research Site, Vinh, Vietnam

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

First Posted Date
2024-03-20
Last Posted Date
2024-08-09
Lead Sponsor
University College, London
Target Recruit Count
8000
Registration Number
NCT06320067
Locations
🇬🇧

University College London Hospitals NHS Foundation Trust, London, United Kingdom

🇬🇧

The Royal Marsden Hospital, Sutton, United Kingdom

🇬🇧

Royal Devon University Hospital Trust, Exeter, United Kingdom

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

First Posted Date
2024-03-20
Last Posted Date
2024-03-20
Lead Sponsor
Shanghai JMT-Bio Inc.
Target Recruit Count
534
Registration Number
NCT06319313

Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

First Posted Date
2024-03-15
Last Posted Date
2024-03-15
Lead Sponsor
Nizhny Novgorod Regional Clinical Oncology Center
Target Recruit Count
106
Registration Number
NCT06313801
Locations
🇷🇺

Research Institute of Clinical Oncology "Nizhny Novgorod Regional Clinical Oncological Dispensary", Nizhny Novgorod, Russian Federation

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

First Posted Date
2024-03-12
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
488
Registration Number
NCT06304974
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy